Press Release

CD BIOPARTICLES LAUNCHES MRNA TRANSFECTION REAGENTS FOR RESEARCH APPLICATIONS



CD Bioparticles recently introduced a line of highly efficient mRNA Transfection Reagents with low toxicity for research applications.

FOR IMMEDIATE RELEASE

29/03/2023

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently introduced a line of highly efficient mRNA Transfection Reagents with low toxicity for research applications, including the mRNA Transfection Reagent, Stem mRNA Transfection Reagent, and mRNA/gRNA Transfection Reagent.

mRNA transfection is the process of introducing and expressing mRNA fragments in cells. In vitro transcribed or synthesized mRNA can be transfected directly into cells. Due to the elimination of the transcription process, mRNA transfection involves only translation and yields faster and more direct results than DNA transfection. Of course, mRNA transfection is limited to instantaneous expressions. Unlike DNA and viral vectors, mRNA will not be inserted into the host genomes that modify genetic information, and proteins encoded by mRNA fragments will only be expressed instantaneously and then degraded rapidly, minimizing the risk of gene integration and being highly safe. Moreover, compared with proteins and viruses, which encounter rapid degradation, mRNA fragments can efficiently express desired proteins within the cellular environment with a simpler preparation process, lower cost, and easier industrial manufacturing pipeline.

However, various challenges can arise during research. For instance, mRNA is a single-stranded, unstable, and degradable fragment, and electrostatic repulsion makes it harder for mRNA molecules to cross cell membranes. Additionally, mRNA synthesized in vitro is inefficient for in vivo use, as it is not a stable macromolecule and is sensitive to shear stress. Furthermore, the short mRNA half-life of in vivo tends to limit sufficient protein expression.

With customized delivery strategies, precise design and transformation of drugs/drug-loaded cargos, and advanced technology platforms, CD Bioparticles now offers a series of mRNA Transfection Reagents for researchers to assist the transfection of lipid vectors for mRNA into target cells. In addition, these new reagents can be applied in various fields, such as mRNA-base vaccine therapy for malignant tumors, protein replacement therapy, and gene editing using mRNA recombination technology. mRNA vaccines protect against infectious diseases like influenza, rabies, HIV and Zika virus infections.

This mRNA Transfection Reagent (Catalog: WHM-OB24, unit size of 50 µL, 500 µL, 1 mL, and 5x1 mL) is designed for mRNA transfection with high efficiency and low toxicity. It has several advantages over plasmid DNA delivery, as nuclear absorption is not required and the translation of mRNA into protein occurs in the cytoplasm, resulting in faster protein expression than DNA transfection and no genome integration. Additionally, it expresses proteins in a completely promoter-independent manner.

For more information about mRNA Transfection Reagents or other transfection products, please visit CD Bioparticles at https://www.cd-bioparticles.net.

About CD Bioparticles

CD Bioparticles is an established drug delivery company that provides customized solutions for novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.

Tags:
mRNA Transfection Reagents  |    |  

---

Organisation Profile:
CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems.






Press release contact details for CD Bioparticles

NameCD Bioparticles
Tel1-631-346-0027
Fax
Email
Websitehttps://www.cd-bioparticles.net/
OrganisationCD Bioparticles
Address
Town
County0
Postcode




Other press releases from CD Bioparticles

CD Bioparticles Launches Gene Silencing for Bio-research Application
CD Bioparticles Launches Gel Permeation Chromatography Resins
CD Bioparticles Introduces Reversed Phase Chromatography Resins for Biological Analysis
CD Bioparticles Launches mRNA Transfection Reagents for Research Applications
CD Bioparticles Launches Normal Phase Chromatography Resins for Chromatographic Analysis
CD Bioparticles Launches 3D Transfection Reagents for Bio-research Applications
CD Bioparticles Launches Affinity Chromatography Resins for Laboratory Usage
CD Bioparticles Announces Carrageenans for Scientific Applications
CD Bioparticles Launches New Chromatography Resins for Improved Analysis and Preparation of Chiral Compounds
CD Bioparticles Launches New Alginic Acids for Research Applications
CD Bioparticles Launches Locust Bean Gum for Biopharmaceutical Applications
CD Bioparticles Announces New PLGA-Based Drug Delivery Systems for In Vitro and In Vivo Applications
CD Bioparticles Launches New Line of Bioinks for 3D Bioprinting
CD Bioparticles Launches New Quantum Dots Labeling & Conjugation Kits
CD Bioparticles Introduces New Extraction and Purification Kits for Rapid and Reliable DNA Isolation
CD Bioparticles Launches New Tissue Engineering Scaffolds for Researchers
CD Bioparticles Launches New Line of Polystyrene Particles Conjugated with Biomolecules
CD Bioparticles Launches 3D Cell Culture Substrate for Bio-research
CD Bioparticles Announces the Launch of New Flow Cytometry Particles
CD Bioparticles Introduces the Launch of Engineered Tissue Scaffolds
CD Bioparticles Announces Polyamino Acids for Drug Delivery Applications
CD Bioparticles Launches New Line of Functional Polystyrene Particles
CD Bioparticles Announces Expanded Offerings of Polydimethylsiloxane for Cutting-Edge Research
CD Bioparticles Unveils Versatile Plain Polystyrene Particles for Diverse Bioresearch Applications
CD Bioparticles Launches New Range of Low PDI Polymers for Drug Delivery Applications
CD Bioparticles Launches New Line of Particles for Solid Phase Organic Synthesis
CD Bioparticles Introduces Innovative Agarose Particles for Purification of Proteins and Antibodies
CD Bioparticles Announces New Line of Polyacrylamides for Drug Delivery Studies
CD Bioparticles Announces Versatile Basic Agarose Particles for Efficient Biomolecule Separation
CD Bioparticles Introduces New Polyolefin Family Polymers for Drug Delivery Applications
CD Bioparticles Announces New Line of Conjugated Agarose Particles for Affinity Separation and Purification
CD Bioparticles Announces Offering of Polystyrene Family Polymers for Drug Delivery
CD Bioparticles Announces Comprehensive Assay Portfolio for mRNA-LNP Vaccine Development
CD Bioparticles Introduces Functional Agarose Particles for Biomedical Research Applications
CD Bioparticles Announces Advanced Capabilities in Customized Liposomes for Targeted Delivery
CD Bioparticles Simplifies Multi-Analyte Detection with Advanced Multiplex Particles

Disclaimer:
Issuers of the press releases are solely responsible for the content of their press releases. Connect2business.co.uk cannot be held liable for the content posted by others to this website.